FONTEYNE PAUL R. has filed 24 insider transactions across 2 companies since January 2023.
Most recent transaction: a disposition of 5748 shares of Apellis Pharmaceuticals, Inc. ($APLS) on May 14, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Stock Option (right to buy) | 5748 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.00% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Common Stock | 3062 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.00% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Common Stock | 5744 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.00% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Common Stock | 7961 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.01% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Common Stock | 3544 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.00% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Common Stock | 3877 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.00% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Stock Option (right to buy) | 14684 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.01% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Stock Option (right to buy) | 37500 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.03% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Stock Option (right to buy) | 11199 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.01% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Stock Option (right to buy) | 8554 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.01% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Stock Option (right to buy) | 7441 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.01% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | D | Stock Option (right to buy) | 27600 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.02% |
| May 14, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Not found | U | Common Stock | 30666 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.02% |
| Jan. 1, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Director | A | Stock Option (Right to Buy) | 14684 | $0.00 | 14,684.0000 | 130,067,000 | 9999.99% | 0.01% |
| Jan. 1, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Director | A | Common Stock | 7961 | $0.00 | 30,666.0000 | 130,067,000 | 35.06% | 0.01% |
| June 5, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | FONTEYNE PAUL R. | Not found | A | Stock Option (right to buy) | 25000 | $0.00 | 25,000.0000 | 88,602,468 | 9999.99% | 0.03% |
| Jan. 1, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Director | A | Stock Option (Right to Buy) | 11199 | $0.00 | 11,199.0000 | 123,905,000 | 9999.99% | 0.01% |
| Jan. 1, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Director | A | Common Stock | 6267 | $0.00 | 22,705.0000 | 123,905,000 | 38.13% | 0.01% |
| June 6, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | FONTEYNE PAUL R. | Not found | A | Stock Option (right to buy) | 25000 | $0.00 | 25,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Director | A | Stock Option (Right to Buy) | 5748 | $59.86 | 5,748.0000 | 118,678,000 | 9999.99% | 0.00% |
| Jan. 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Director | A | Common Stock | 3341 | $0.00 | 16,438.0000 | 118,678,000 | 25.51% | 0.00% |
| June 8, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | FONTEYNE PAUL R. | Director | A | Stock Option (right to buy) | 16985 | $0.00 | 16,985.0000 | 0 | 9999.99% | 0.00% |
| Jan. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Director | A | Common Stock | 3867 | $0.00 | 13,097.0000 | 106,114,000 | 41.90% | 0.00% |
| Jan. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | FONTEYNE PAUL R. | Director | A | Stock Option (Right to Buy) | 7441 | $0.00 | 7,441.0000 | 106,114,000 | 9999.99% | 0.01% |